Multiple Myeloma Clinical Trial
— TEC-CAREOfficial title:
Analysis of Effectiveness and Safety of Teclistamab in Relapsed and Refractory Multiple Myeloma Patients: a Collaborative Janssen - IFM Study IFM 2023-01: TEC-CARE
200 adult patients with multiple myeloma receiving teclistamb will be included. Effectiveness, safety, and condition of use of teclistamab in early access program (post-MA) will be assessed. Primary objective is the evaluation of overall response rate (ORR) of teclistamab according to IMWG criteria. This is a multicenter, prospective, observational study.
| Status | Recruiting |
| Enrollment | 200 |
| Est. completion date | September 2026 |
| Est. primary completion date | September 2026 |
| Accepts healthy volunteers | No |
| Gender | All |
| Age group | 18 Years and older |
| Eligibility | Inclusion Criteria: - Adult patient (=18 years) with multiple myeloma who will receive at least one dose of teclistamab (first dose of the step-up dose) Exclusion Criteria: - Patients alive at the start of the study who did not receive study information or who objected to the collection of data - Patients who received teclistamab as part of an interventional clinical trial - Patients who are initiating teclistamab as part of a current interventional clinical trial |
| Country | Name | City | State |
|---|---|---|---|
| France | CH d'ANNECY | Annecy | |
| France | Hopital de la cote Basque | Bayonne | |
| France | CHU Bordeaux | Bordeaux | |
| France | CHU CAEN | Caen | |
| France | Chu Dijon | Dijon | |
| France | CH Dunkerque | Dunkerque | |
| France | CHU de Lille | Lille | |
| France | CHU de Lyon | Lyon | |
| France | Institut Paoli Calmette | Marseille | |
| France | CH de METZ | Metz | |
| France | Chu de Nantes | Nantes | |
| France | CHU de Nice | Nice | |
| France | Hopital Necker | Paris | |
| France | Hopital saint louis | Paris | |
| France | CH Perpignan | Perpignan | |
| France | Hopital Novo | Pontoise | |
| France | Chu de Rennes | Rennes | |
| France | CHU Toulouse | Toulouse | |
| France | CHU de Tours | Tours | |
| France | CH Bretagne Atlantique | Vannes |
| Lead Sponsor | Collaborator |
|---|---|
| Intergroupe Francophone du Myelome | Janssen-Cilag Ltd. |
France,
| Type | Measure | Description | Time frame | Safety issue |
|---|---|---|---|---|
| Primary | overall response rate (ORR) of teclistamab according to IMWG criteria | ORR is defined as the proportion of subjects who achieve a PR or better according to IMWG criteria. | 6 months | |
| Primary | overall response rate (ORR) of teclistamab according to IMWG criteria | ORR is defined as the proportion of subjects who achieve a PR or better according to IMWG criteria. | 24 months | |
| Secondary | Effectiveness of teclistamab | Progression Free Survival 1 and 2 (PFS) | 24 months | |
| Secondary | Effectiveness of teclistamab | Overall survival (OS) | 24 months | |
| Secondary | Effectiveness of teclistamab | Duration of overall response (DOR) | 24 months | |
| Secondary | Effectiveness of teclistamab | Response rate (sCR, CR, VGPR, PR) | 24 months | |
| Secondary | Effectiveness of teclistamab | Time to best response | 24 months | |
| Secondary | Effectiveness of teclistamab | Time to next treatment (TTNT) | 24 months | |
| Secondary | Effectiveness of teclistamab | Time to discontinuation (TTD) | 24 months | |
| Secondary | Adverse events of interest | ICANS, CSR and infections | 24 months | |
| Secondary | Conditions of use | Patients' profiles (demographics characteristics and medical history) - Injection facilities and schedules during step-up dosing phase |
1 month | |
| Secondary | Conditions of use | Patients' profiles (demographics characteristics and medical history) - Injection facilities and schedules during follow up phase |
24 months |
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT05027594 -
Ph I Study in Adult Patients With Relapsed or Refractory Multiple Myeloma
|
Phase 1 | |
| Completed |
NCT02412878 -
Once-weekly Versus Twice-weekly Carfilzomib in Combination With Dexamethasone in Adults With Relapsed and Refractory Multiple Myeloma
|
Phase 3 | |
| Completed |
NCT01947140 -
Pralatrexate + Romidepsin in Relapsed/Refractory Lymphoid Malignancies
|
Phase 1/Phase 2 | |
| Recruiting |
NCT05971056 -
Providing Cancer Care Closer to Home for Patients With Multiple Myeloma
|
N/A | |
| Recruiting |
NCT05243797 -
Phase 3 Study of Teclistamab in Combination With Lenalidomide and Teclistamab Alone Versus Lenalidomide Alone in Participants With Newly Diagnosed Multiple Myeloma as Maintenance Therapy Following Autologous Stem Cell Transplantation
|
Phase 3 | |
| Active, not recruiting |
NCT04555551 -
MCARH109 Chimeric Antigen Receptor (CAR) Modified T Cells for the Treatment of Multiple Myeloma
|
Phase 1 | |
| Recruiting |
NCT05618041 -
The Safety and Efficay Investigation of CAR-T Cell Therapy for Patients With Hematological Malignancies
|
N/A | |
| Active, not recruiting |
NCT03844048 -
An Extension Study of Venetoclax for Subjects Who Have Completed a Prior Venetoclax Clinical Trial
|
Phase 3 | |
| Recruiting |
NCT03412877 -
Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Neoantigens in People With Metastatic Cancer
|
Phase 2 | |
| Completed |
NCT02916979 -
Myeloid-Derived Suppressor Cells and Checkpoint Immune Regulators' Expression in Allogeneic SCT Using FluBuATG
|
Phase 1 | |
| Recruiting |
NCT03570983 -
A Trial Comparing Single Agent Melphalan to Carmustine, Etoposide, Cytarabine, and Melphalan (BEAM) as a Preparative Regimen for Patients With Multiple Myeloma Undergoing High Dose Therapy Followed by Autologous Stem Cell Reinfusion
|
Phase 2 | |
| Terminated |
NCT03399448 -
NY-ESO-1-redirected CRISPR (TCRendo and PD1) Edited T Cells (NYCE T Cells)
|
Phase 1 | |
| Completed |
NCT03665155 -
First-in- Human Imaging of Multiple Myeloma Using 89Zr-DFO-daratumumab, a CD38-targeting Monoclonal Antibody
|
Phase 1/Phase 2 | |
| Completed |
NCT02812706 -
Isatuximab Single Agent Study in Japanese Relapsed AND Refractory Multiple Myeloma Patients
|
Phase 1/Phase 2 | |
| Active, not recruiting |
NCT05024045 -
Study of Oral LOXO-338 in Patients With Advanced Blood Cancers
|
Phase 1 | |
| Active, not recruiting |
NCT03989414 -
A Study to Determine the Recommended Dose and Regimen and to Evaluate the Safety and Preliminary Efficacy of CC-92480 in Combination With Standard Treatments in Participants With Relapsed or Refractory Multiple Myeloma (RRMM) and Newly Diagnosed Multiple Myeloma (NDMM)
|
Phase 1/Phase 2 | |
| Active, not recruiting |
NCT03792763 -
Denosumab for High Risk SMM and SLiM CRAB Positive, Early Myeloma Patients
|
Phase 2 | |
| Withdrawn |
NCT03608501 -
A Study of Ixazomib, Thalidomide and Dexamethasone in Newly Diagnosed and Treatment-naive Multiple Myeloma (MM) Participants Non-eligible for Autologous Stem-cell Transplantation
|
Phase 2 | |
| Recruiting |
NCT04537442 -
Clinical Study to Evaluate the Safety and Efficacy of IM21 CAR-T Cells in the Treatment of Elderly Patients With Relapsed or Refractory Multiple Myeloma
|
Phase 1 | |
| Completed |
NCT02546167 -
CART-BCMA Cells for Multiple Myeloma
|
Phase 1 |